Background: While pharmacotherapy with intravenous ceftriaxone, a third-generation cephalosporin, is a potential treatment of Lyme neuroborreliosis, there is concern that it can cause the formation of biliary sludge, leading to hepatobiliary complications such as biliary colic, jaundice and cholelithiasis, which are reflected in changes in serum levels of bilirubin and markers of cholestatic liver injury (alkaline phosphatase and γ-glutamyltranspeptidase). It has been suggested that the naturally occurring substances α-lipoic acid and glutathione may be helpful in preventing hepatic disease. α-Lipoic acid exhibits antioxidant, anti-inflammatory and anti-apoptotic activities in the liver, while glutathione serves as a sulfhydryl buffer. The aim of this study was to determine whether co-administration of α-lipoic acid and glutathione is associated with significant changes in serum levels of bilirubin, alkaline phosphatase and γ-glutamyltranspeptidase during the treatment of Lyme neuroborreliosis with long-term intravenous ceftriaxone.
Methods: Serum levels of bilirubin, alkaline phosphatase and γ-glutamyltranspeptidase were measured in 42 serologically positive Lyme neuroborreliosis patients before and after long-term treatment with intravenous ceftriaxone (2–4 g daily) with co-administration of oral/intravenous α-lipoic acid (600 mg daily) and glutathione (100 mg orally or 0.6–2.4 g intravenously daily).
Results: None of the patients developed biliary colic and there were no significant changes in serum bilirubin, alkaline phosphatase or γ-glutamyltranspeptidase levels over the course of the intravenous ceftriaxone treatment (mean length 75.0 days).
Conclusions: Co-administration of α-lipoic acid and glutathione is associated with no significant changes in serum bilirubin, alkaline phosphatase or γ-glutamyltranspeptidase levels during the treatment of neuroborreliosis with intravenous ceftriaxone.
All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report or in the decision to submit the report for publication.
1. BiesiadaG, CzepielJ, LesniakMR, GarlickiA, MachT. Lyme disease: review . Arch Med Sci2012;8:978–82.Search in Google Scholar
3. OweckiMK, KozubskiW. Clinical spectrum of neuroborreliosis . Wiad Lek2007;60:167–70.Search in Google Scholar
4. PoplawskaR, SzulcA, ZajkowskaJ, PancewiczS. Neuroborreliosis: a psychiatric problem? . Psychiatr Pol1999;33:241–50.Search in Google Scholar
5. KaiserR. Clinical courses of acute and chronic neuroborreliosis following treatment with ceftriaxone . Nervenarzt2004;75:553–7.Search in Google Scholar
7. CDC. Ceftriaxone-associated biliary complications of treatment of suspected disseminated Lyme disease – New Jersey, 1990–1992 . J Am Med Assoc1993;269:979–80.10.1001/jama.269.8.979Search in Google Scholar
8. PfisterHW, Preac-MursicV, WilskeB, SchielkeE, SorgelF, EinhauplKM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis . J Infect Dis1991;163:311–18.10.1093/infdis/163.2.311Search in Google Scholar
9. AronsonJK, DukesMN. Meyler’s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions, 15th ed. Amsterdam: Elsevier, 2006.Search in Google Scholar
11. BruntonLL, ChabnerB. Knollmann BrC: Goodman & Gilman’s pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill, 2011.Search in Google Scholar
12. BickfordCL, SpencerAP. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature . Pharmacotherapy2005;25:1389–95.10.1592/phco.2005.25.10.1389Search in Google Scholar
13. XiaX, SuC, FuJ, ZhangP, JiangX, XuD, et al. Role of alpha-lipoic acid in LPS/d-GalN induced fulminant hepatic failure in mice: studies on oxidative stress, inflammation and apoptosis . Int Immunopharmacol2014;22:293–302.10.1016/j.intimp.2014.07.008Search in Google Scholar
14. LiY, MaQG, ZhaoLH, GuoYQ, DuanGX, ZhangJY, et al. Protective efficacy of alpha-lipoic acid against aflatoxinB1-induced oxidative damage in the liver . Asian Australas J Anim Sci2014;27:907–15.10.5713/ajas.2013.13588Search in Google Scholar
15. BustamanteJ, LodgeJK, MarcocciL, TritschlerHJ, PackerL, RihnBH. Alpha-lipoic acid in liver metabolism and disease . Free Radic Biol Med1998;24:1023–39.10.1016/S0891-5849(97)00371-7Search in Google Scholar
16. ChenY, DongH, ThompsonDC, ShertzerHG, NebertDW, VasiliouV. Glutathione defense mechanism in liver injury: insights from animal models . Food Chem Toxicol2013;60:38–44.10.1016/j.fct.2013.07.008Search in Google Scholar PubMed PubMed Central
17. BergJM, TymoczkoJL, StryerL. Biochemistry, 7th ed. New York: W.H. Freeman, 2012.Search in Google Scholar
18. ImperialJC, KeeffeEB. Laboratory tests. In: BaconBR, O’GradyJG, Di BisceglieAM, LakeJR, editors. Comprehensive clinical hepatology, 2nd ed. Philadelphia, PA: Elsevier Mosby, 2006:73–81.Search in Google Scholar
19. IdeT. Effect of dietary alpha-lipoic acid on the mRNA expression of genes involved in drug metabolism and antioxidation system in rat liver . Br J Nutr2014;112:295–308.10.1017/S0007114514000841Search in Google Scholar PubMed
20. SudheeshNP, AjithTA, JanardhananKK. Hepatoprotective effects of DL-alpha-lipoic acid and alpha-tocopherol through amelioration of the mitochondrial oxidative stress in acetaminophen challenged rats . Toxicol Mech Methods2013;23:368–76.10.3109/15376516.2013.769289Search in Google Scholar
21. YamadaM, KaiboriM, TanakaH, HabaraK, HijikawaT, TanakaY, et al. Alpha-lipoic acid prevents the induction of iNOS gene expression through destabilization of its mRNA in proinflammatory cytokine-stimulated hepatocytes . Dig Dis Sci2012;57:943–51.10.1007/s10620-011-2012-4Search in Google Scholar
22. GeenenS, du PreezFB, SnoepJL, FosterAJ, SardaS, KennaJG, et al. Glutathione metabolism modeling: a mechanism for liver drug-robustness and a new biomarker strategy . Biochim Biophys Acta2013;1830:4943–59.10.1016/j.bbagen.2013.04.014Search in Google Scholar
23. DurraniAI, SchwartzH, NaglM, SontagG. Determination of free α-lipoic acid in foodstuffs by HPLC coupled with CEAD and ESI-MS . Food Chem2010;120:1143–8.10.1016/j.foodchem.2009.11.045Search in Google Scholar
©2015 by De Gruyter